Banner Default Image


20,000 people, 7 multinational pharmaceutical companies and over 200 biomedical companies, all on our doorstep.  This is where we established our place in the Pharmaceutical & Healthcare Product Manufacturing Sector.

Our portfolio of clients in this sector is diverse and spans Tablet Making, Consumer Healthcare Products, Generics, Medical Devices, Infection Control Products, Animal Health, Medical Nutrition, Healthcare Equipment & Instruments and Wound Care Products.

The United Kingdom has a strong well-established pharmaceutical sector, composed of domestic companies and inward investors. However, the industry has had numerous challenges over the past five years, including higher costs and price controls, import penetration and the loss of patent protection for some of the most profitable drugs. However, rising life expectancy and an ageing population have boosted demand for some drugs, particularly those for degenerative diseases. Over the past decade, the industry has evolved, with small biotech start-ups being spun out of universities and a growing number of collaborations between industry players taking place.

According to reports, the UK pharmaceutical market was worth $24 billion in 2012 and is forecast to reach $31.7 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 3.5%.

In December 2020, the UK government ordered 100 million doses of the Oxford-AstraZeneca vaccine, the majority of which are being manufactured in the United Kingdom, aiding industry revenue over 2021-22. Overall hospital admissions fell in 2020 due to the outbreak and has created a major backlog of unresolved medical issues. As of March 2021, a total of 4.9 million patients were on the waiting list for treatment according to NHS data. This is expected to cause an increase in demand for pharmaceuticals over the current year as the NHS tackles the backlog. Industry revenue declined in 2020-21, as the coronavirus pandemic disrupted the healthcare sector and caused procedures to be postponed allowing hospitals to focus on their coronavirus responses.

The industry is expected to continue to expand over the next five years, although growth could be limited by patent expirations and competition. Exports may remain under pressure, but they are still anticipated to account for a large share of industry revenue, while imports are expected to continue playing an important role in satisfying domestic demand. Rising life expectancy and an ageing population are anticipated to boost demand for industry products However, patent expirations are likely to continue limiting profit for some players as generic products dominate the market.

​Our experience in this sector is centred around manufacturing operations. We have delivered a wealth of projects across all departments/functions within:

  • Tablet Making

  • Consumer Healthcare Products

  • Generics

  • Medical Devices

  • Infection Control Products

  • Animal Health

  • Medical Nutrition

  • Healthcare Equipment & Instruments

  • Wound Care Products

Back to Sectors